机械循环支持桥接多器官心脏移植的国家结局
基于1986至2019年UNOS成人多器官移植登记数据,研究分析4534例多器官移植等待者(其中2117例接受移植)按机械循环支持(MCS)状态分层的结局。移植后生存在不同MCS类型与无MCS者间无显著差异;等待期ECMO桥接者死亡风险显著高于无MCS者,而心室辅助装置桥接者死亡风险降低。
要点
- 多器官心脏移植后生存在不同MCS类型与无MCS者间无显著差异
- 等待期ECMO桥接者死亡风险显著高于无MCS者(sHR 2.27)
- 等待期心室辅助装置桥接者死亡风险低于无MCS者(sHR 0.78)
核心结论
- 当前应用的MCS似不损害多器官心脏移植患者的生存。
- 等待期数据显示ECMO患者生存显著更差,且不受包括 listed 器官类型在内的术前因素影响。
- 多器官移植等待期生存随器械年代改善。
研究设计与样本
- 回顾性分析UNOS 1986至2019年成人多器官移植登记数据。
- 移植后队列与等待名单队列均按MCS状态分层。
- 移植后队列用Cox回归评估生存,等待名单队列用Fine-Gray竞争风险回归(以移植为竞争风险)。
主要发现
- 研究期间多器官移植等待名单共4534例,其中2117例接受多器官移植。
- 全队列及心-肾亚组中,不同MCS类型与无MCS者移植后生存无显著差异。
- 控制术前特征后,ECMO桥接者等待期死亡风险高于无MCS者(sHR 2.27;95%CI 1.48-3.47;P<.001)。
- 控制术前特征后,心室辅助装置桥接者死亡发生率低于无MCS者(sHR 0.78;95%CI 0.63-0.96;P=.017)。
临床怎么用
- 多器官心脏移植候选者使用VAD桥接等待期死亡风险较低,可考虑作为桥接策略。
- ECMO桥接的多器官移植等待者等待期死亡风险显著升高,需谨慎评估与选择。
- MCS桥接未显示损害移植后生存,支持在合适患者中应用。
局限性
- 为登记数据库回顾性分析,可能存在选择偏倚与未测量混杂。
- 研究跨越1986至2019年,器械年代与围术期管理变化可能影响结果解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known regarding the profile of patients with multiorgan failure listed for simultaneous cardiac transplantation and secondary organ. In addition, few studies have reported how these patients are bridged with mechanical circulatory support (MCS). In this study, we examined national data of patients listed for multiorgan transplantation and their outcomes after bridging with or without MCS. METHODS: United Network for Organ Sharing data were reviewed for adult multiorgan transplantations from 1986 to 2019. Post-transplant patients and total waitlist listings were examined and stratified according to MCS status. Survival was assessed via Cox regression in the post-transplant cohort and Fine-Gray competing risk regression with transplantation as a competing risk in the waitlist cohort. RESULTS: There were 4534 waitlist patients for multiorgan transplant during the study period, of whom 2117 received multiorgan transplants. There was no significant difference in post-transplant survival between the MCS types and those without MCS in the whole cohort and heart-kidney subgroup. Fine-Gray competing risk regression showed that patients bridged with extracorporeal membrane oxygenation had significantly greater waitlist mortality compared with those without MCS when controlling for preoperative characteristics (subdistribution hazard ratio, 2.27; 95% confidence interval, 1.48-3.47; P < .001), whereas those bridged with a ventricular assist device had a decreased incidence of death compared with those without MCS (subdistribution hazard ratio, 0.78; 95% confidence interval, 0.63-0.96; P = .017). CONCLUSIONS: MCS, as currently applied, does not appear to compromise the survival of multiorgan heart transplant patients. Waitlist data show that extracorporeal membrane oxygenation patients have profoundly worse survival irrespective of preoperative factors including organ type listed. Survival on the waitlist for multiorgan transplant has improved across device eras.
引用
- Melehy A, Sanchez JE, Nemeth SK, et al. National outcomes of bridge to multiorgan cardiac transplantation using mechanical circulatory support. J Thorac Cardiovasc Surg. 2021. PMID: 33678503. doi:10.1016/j.jtcvs.2021.01.114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。